Available to mentor
Rodica Pop-Busui, MD, PhD, is the Larry D. Soderquist Professor of Diabetes, a prominent diabetologist at Michigan Medicine and a recognized leader in the field of diabetes and diabetes complications. She is the Vice Chair for Clinical Research in the Department of Internal Medicine and the Associate Director of Clinical Research, Mentoring and Development of the Elizabeth Caswell Diabetes Institute at the University of Michigan. Her research interests involve chronic complications of diabetes, particularly diabetic peripheral and cardiovascular autonomic neuropathy, as well as diabetic foot complications, diabetic kidney disease and cardiovascular disease, and the design and conduct of traditional and pragmatic clinical trials for patients with diabetes.
Dr. Pop-Busui has published more than 200 peer-reviewed manuscripts and book chapters, and received awards from the American Diabetes Association (ADA) and the University of Michigan. She has chaired the 2017 American Diabetes Association Position Statement on Diabetic Neuropathy, and has served as Chair of the American Diabetes Association Scientific Research Review Clinical and Chair of the ADA Diabetes & Cardiovascular Disease Interest Group. Most recently she has been elected to chair the Precision Prognostic in Type 1 Diabetes Working Group of the American Diabetes Association/European Association for the Study of Diabetes.
She has been PI/CoI and member of the Steering Committee in several landmark diabetes clinical trials including: the NHLBI-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the NIDDK funded Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications, Preventing Early Renal Loss in Type 1 Diabetes (PERL), Bypass Angioplasty Revascularization Diabetes 2 (BARI- 2D) and Glycemia Reduction Approaches in Type 2 Diabetes-A Comparative Effectiveness Study (GRADE) . In addition, she designed and leads several investigator-initiated studies funded by NIDDK and Pharma to unveil disease modifying agents for diabetic neuropathy and other chronic diabetes complications.
Dr Pop-Busui is the corresponding principal investigator and member of the Steering Committee of the recently established NIDDK Diabetes Foot Consortium and one of the principal investigators of the JDRF Center of Excellence at the University of Michigan .
Dr Pop-Busui had also mentored junior physician scientists and other trainees in their career developments, has implemented and directs the Clinical Trials Academy at the University of Michigan, and is the PI on the Steno North American Fellowship funded by Novo Nordisk Foundation to foster new collaborations and mentoring between physicians scientists from the University of Michigan and the 5 Steno Diabetes Centers in Denmark.
-
MDUniversity of Medcine and Pharmacy Victor Babes, Timisoara
-
PhDUniversity of Medicine and Pharmacy Victor Babes, Timisoara
-
Center MemberGlobal REACH
-
Center MemberInstitute for Healthcare Policy and Innovation
-
Center MemberMM-PKUHSC Joint Institute
-
Center MemberCaswell Diabetes Institute
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
-
Center MemberPrecision Health Initiative
Dr. Pop-Busui has concentrated her scholarship and research efforts on translational and clinical research focused in understanding the mechanisms of diabetic complications, particularly of diabetic peripheral neuropathy and cardiovascular autonomic neuropathy, and to understand their role in the development of the high cardiovascular risk complicating diabetes. As a result of her efforts, her research has been funded by the National Institute of Health/National Heart, Lung and Blood Institute, the American Diabetes Association, the Juvenile Diabetes Research Foundation, other foundations and industry. She also is and has been a PI or co-PI on several landmark diabetes trials funded by the National Institute of Health, such as the NHLBI-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the NHLBI-funded Bypass Angioplasty Revascularization Investigation Type 2 Diabetes (BARI 2D) study, and the NIDDK-funded Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC).
-
Mizokami-Stout K, Oshman L, Diez H, Griauzde D, Lee J, Khosrovaneh K, Bhomia N, Kim N, Rau J, Reiss J, Busui R. Diabetes, 2024 Jun 14; 73 (Supplement_1):Proceeding / Abstract / Poster1073-P: Trends in Guideline-Directed Medication Therapy for Type 2 Diabetes in a Statewide Quality Collaborative between 2018–2023
DOI:10.2337/db24-1073-p -
BRAFFETT BH, IPPOLITO GM, AMIGHI A, WESSELLS H, TRAPANI VR, JACOBSON AM, BUSUI R, SARMA AV. Diabetes, 2024 Jun 14; 73 (Supplement_1):Journal Article1257-P: Post-void Residual Urine in Men and Women with Long-Standing Type 1 Diabetes (T1D)—The UroEDIC Study
DOI:10.2337/db24-1257-p -
SCHMIDT BM, SPINO C, ROY S, GORDILLO G, HOLMES CM, SEN CK, BUSUI R. Diabetes, 2024 Jun 14; 73 (Supplement_1):Journal Article311-OR: High Transepidermal Water Loss (TEWL) Associates with Failure to Maintain Wound Closure in Diabetic Foot Ulcers
DOI:10.2337/db24-311-or -
ANG L, HUANG Y, MARTIN C, MIZOKAMI-STOUT KR, KUEI LIN Y, VASBINDER A, BANERJEE M, HAYEK S, FELDMAN EL, BUSUI R. Diabetes, 2024 Jun 14; 73 (Supplement_1):Proceeding / Abstract / Poster9-OR: ADA Presidents' Select Abstract: Targeting Inflammation with Salsalate in Type 1 Diabetes Neuropathy (TINSAL-T1DN Trial)
DOI:10.2337/db24-9-or -
Lane G, Amighi A, Wessells H, Trapani V, Clemens Q, Busui R, Braffett B, Sarma A. Journal of Urology, 2024 May; 211 (5S): e1232Journal ArticleMP75-04 POST VOID RESIDUAL URINE IN MEN AND WOMEN WITH LONG STANDING TYPE 1 DIABETES (T1D)
DOI:10.1097/01.ju.0001008676.21744.5f.04 -
Klonoff DC, Wang J, Rodbard D, Kohn MA, Li C, Liepmann D, Kerr D, Ahn D, Peters AL, Umpierrez GE, Seley JJ, Xu NY, Nguyen KT, Simonson G, Agus MSD, Al-Sofiani ME, Armaiz-Pena G, Bailey TS, Basu A, Battelino T, Bekele SY, Benhamou P-Y, Bequette BW, Blevins T, Breton MD, Castle JR, Chase JG, Chen KY, Choudhary P, Clements MA, Close KL, Cook CB, Danne T, Doyle FJ, Drincic A, Dungan KM, Edelman SV, Ejskjaer N, Espinoza JC, Fleming GA, Forlenza GP, Freckmann G, Galindo RJ, Gomez AM, Gutow HA, Heinemann L, Hirsch IB, Hoang TD, Hovorka R, Jendle JH, Ji L, Joshi SR, Joubert M, Koliwad SK, Lal RA, Lansang MC, Lee W-AA, Leelarathna L, Leiter LA, Lind M, Litchman ML, Mader JK, Mahoney KM, Mankovsky B, Masharani U, Mathioudakis NN, Mayorov A, Messler J, Miller JD, Mohan V, Nichols JH, Nørgaard K, O'Neal DN, Pasquel FJ, Philis-Tsimikas A, Pieber T, Phillip M, Polonsky WH, Pop-Busui R, Rayman G, Rhee E-J, Russell SJ, Shah VN, Sherr JL, Sode K, Spanakis EK, Wake DJ, Waki K, Wallia A, Weinberg ME, Wolpert H, Wright EE, Zilbermint M, Kovatchev B. J Diabetes Sci Technol, 2023 Sep; 17 (5): 1226 - 1242.Journal ArticleA Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings.
DOI:10.1177/19322968221085273 PMID: 35348391 -
McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JFE, Marx N, Mulvagh SL, Poulter N, Engelmann MDM, Hovingh GK, Ripa MS, Gislum M, Brown-Frandsen K, Buse JB. Diabetes Obes Metab, 2023 Jul; 25 (7): 1932 - 1941.Journal ArticleEffects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
DOI:10.1111/dom.15058 PMID: 36945734 -
REYNOLDS EL, MIZOKAMI-STOUT KR, PUTNAM N, BANERJEE M, ALBRIGHT D, LEE JM, BUSUI R, FELDMAN EL, CALLAGHAN BC. Diabetes, 2023 Jun 20; 72 (Supplement_1):Proceeding / Abstract / Poster1010-P: Cost and Utilization of Health Care Services for Persons with Diabetes
DOI:10.2337/db23-1010-p